Substituted Imidazoles Disrupt KRAS Dimerization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for KRAS-driven cancers, particularly pancreatic, colorectal, and lung cancers, lack effective therapeutics targeting KRAS G12D and G12V mutants, as existing inhibitors are either non-selective or ineffective against these prevalent mutations.
Innovation Solution
Development of novel chemical compounds that selectively inhibit KRAS G12D and G12V mutants by disrupting their dimerization, thereby targeting the oncogenic potential of these mutants without affecting wild-type KRAS.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing KRAS inhibitors are used, then KRAS signaling is inhibited, but selectivity between mutant and wild-type KRAS is lost
Solution Approach 1:
The patent applies local quality by designing compounds that specifically target the unique structural features of mutant KRAS (such as the G12C cysteine residue or dimerization interface) while sparing wild-type KRAS. The compounds incorporate functional groups that interact with mutation-specific residues, creating localized selective inhibition at the mutant protein level without affecting the wild-type protein's normal function.
Solution Approach 2:
The patent segments the KRAS inhibition approach by developing compounds that specifically disrupt mutant KRAS dimerization or bind to mutation-specific pockets, separating the inhibition mechanism from general KRAS function. This segmentation allows selective targeting of mutant forms through their unique structural characteristics rather than pan-RAS inhibition.
2Reliability
If KRAS dimerization is disrupted to inhibit signaling, then mutant KRAS activity is reduced, but mechanism complexity increases
Solution Approach 1:
The patent extracts the dimerization interface or critical dimerization residues as the specific target for compound binding. By focusing on removing or blocking the dimerization function specifically (rather than inhibiting all KRAS activities), the mechanism becomes more targeted and less complex, as it exploits a specific structural feature unique to mutant KRAS.
Solution Approach 2:
Instead of directly inhibiting the catalytic activity of KRAS, the patent inverts the approach by targeting the dimerization function - a prerequisite for oncogenic signaling. This indirect approach simplifies the mechanism by disrupting the upstream regulatory step that enables mutant KRAS pathogenicity, rather than directly blocking downstream effector interactions.
3Adaptability or versatility
If selective inhibitors for KRAS G12D and G12V are developed, then treatment options for prevalent mutations are improved, but development time and resources increase
Solution Approach 1:
The patent applies universality by designing a compound series based on a common core structure that can be adapted to target different KRAS mutations (G12C, G12D, G12V) through systematic modification of functional groups. This multi-functional platform approach allows simultaneous development of inhibitors for multiple mutation types, reducing overall development time and resources compared to creating entirely separate inhibitor programs for each mutation.
Data Source
AI summary
There are provided compounds, their preparation and their use in the treatment of KRAS-driven cancers. The compounds according to the invention (general formula Class III) disrupt dimerization of KRAS and are inhibitors of KRAS mutants such as KRAS G12D, KRAS G12V and KRAS 12C. Embodiments of the compounds according to the invention are selective inhibitors of KRAS mutants over the wild-type (WT) KRAS.